Gelonghui, January 26, 丨 Boan Biotech (06955.HK) announced that the company has signed an agreement with Health Yuan Pharmaceutical Group Co., Ltd. The agreement relates to the exclusive authorized development and commercialization of the company's ongoing product BA2101 injection for the treatment of asthma and chronic obstructive pulmonary disease (COPD) and other respiratory diseases.
According to the agreement, the company will grant Health Yuan exclusive rights to carry out the exclusive development, registration, production and commercialization of this product for indications in this field in mainland China. The company, on the other hand, continues to hold all rights relating to the product in relation to all other indications outside of this field in the agreement area, as well as all rights of the product for all indications outside the agreement area. In exchange for an exclusive license, Health Yuan will pay the company a down payment and development milestone payment after signing the agreement. Health Yuan also agreed to pay potential sales milestone payments and sales commissions to the company based on the net sales of the product in the agreed region. None of these payments are refundable. In addition, Health Yuan is responsible for all clinical and subsequent development activities of the product in this field in the agreement area and bears related costs.
BA2101 injection was independently developed by the company. It is an innovative long-acting all-human monoclonal IgG4 antibody targeting interleukin-4 receptor subunit α (IL-4Rα). It can simultaneously inhibit IL-4 and IL-13 signaling pathways, regulate Th2 inflammation, and reduce eosinophil content and IgE levels. This product is intended to treat allergic diseases caused by Th2 inflammation. Currently, the company has obtained clinical trial approval for atopic dermatitis, asthma, COPD, chronic sinusitis with nasal polyps, prurigo nodosum, and chronic spontaneous urticaria.
The current partner Health Yuan is a leading Chinese company in the field of respiratory treatment. It lays out key varieties and forms a rich product portfolio around respiratory medication, and has a dedicated respiratory marketing team across the country, and is in a leading position in this treatment field. Through this cooperation, the company and Health Yuan will actively use their respective advantages in R&D and commercialization to accelerate the clinical development process of BA2101 injections in diseases such as asthma and COPD. Furthermore, with efficient clinical development and promotion capabilities, the company will also accelerate the development of more indications to benefit patients as soon as possible.